Early results of human atrial natriuretic peptide infusion in non-dialysis patients with chronic kidney disease undergoing isolated coronary artery bypass grafting: the NU-HIT trial for CKD-II

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

Chronic kidney disease (CKD) is an important risk factor for cardiac surgery.

In the present study, a subanalysis was performed on patients registered in the NU-HIT trial for CKD from the standpoint of renin-angiotensin system, natriuresis and renal function.

Who Took Part

The study group was 303 patients.

303 patients with CKD who underwent isolated CABG were divided into a group that received carperitide infusion and another group without carperitide.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind ANP (Atrial Natriuretic Peptide) study, the assignments were hidden from both participants and investigators until the end.

The renin activity, angiotensin-II, aldosterone, urine-sodium, urine- creatinine, fractional sodium excretion, renal failure index, and BNP levels.

What Was Measured

The subject headings attached to it are Atrial Natriuretic Factor, Biomarkers, Cardiopulmonary Bypass, Coronary Artery Bypass, Coronary Artery Disease, Infusions, Parenteral and Japan.

What This Means in Plain Language

The paper is a randomized and double-blind study of ANP (Atrial Natriuretic Peptide) in 303 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia), a journal based in Japan.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.